Sodium Valproate
The question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 July 2025 to Question 68387 on Epilepsy and Pregnancy: Sodium Valproate, what his Departments planned timeline is for establishing a centralised register caputring Pregnancy Prevention Programme interventions and acknowledgements, linked to prescribing data.
Answered by Karin Smyth
NHS England has worked collaboratively with the Medicines and Healthcare products Regulatory Agency on the safer use of valproate containing medicines. The best way to a centralised register is through the single patient record and the use of this to populate the federated data platfor, which would allow for the functionality of a centralised register. This is enabled by the Transformation Directorate to ensure that clinical care can be effectively and accurately coded.
The Medicines and Pregnancy Register monitors prescribing of valproate and highlights the number of pregnancies potentially exposed to valproate. This data demonstrates a reduction in prescribing valproate to women and girls as well as a reduction in the number of possible exposed pregnancies since the Pregnancy Prevention Programme (PPP) was introduced in 2018. Analysis shows the implementation of the PPP by ICBs is consistent across the country. The register is available at the following link:
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →